Recombinant Human Coagulation Factor VIII, Procoagulant Component

• Cat.No.: F8-125H
• Product Overview: Recombinant Human F8 lacks central region of B-domain region and is purified by proprietary chromatographic techniques.

Specification

• Cat. No.: F8-125H
• Description: This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder.
• Source: CHO Cells
• Molecular Mass: Antihemophilic Facor Human Recombinant produced in CHO is a glycosylated polypeptide chain having a total amino acids of 1438 (170kd) and consisting of two dimer chains 80 kD and 90 kD.
• Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder.
• Formulation: The protein was lyophilized from a solution containing 50mM histidine, 0.3M NaCl, 5mM CaCl2, 0.02% Tween 80, 20mM sucrose, pH- 6.8.
• Purity: Greater than 97.0% as determined by SDS-PAGE.
• Solubility: It is recommended to reconstitute the lyophilized Factor-VIII in 1ml sterile 18MΩ-cm H2O, which can then be further diluted to other aqueous solutions.
• Biological Activity: The specific activity was found to be 7428IU/mg.
• Stability: Lyophilized Factor-VIII although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution Factor-VIII should be stored at 4°C between 2-7 days and for future use below -18°C. Please prevent freeze-thaw cycles
• OfficialSymbol: F8
• Tag: Non

Gene Information

• Gene Name: F8 coagulation factor VIII, procoagulant component [ Homo sapiens ]
• Synonyms: F8; coagulation factor VIII, procoagulant component; AHF; F8B; F8C; HEMA; FVIII; DXS1253E; Factor VIIIF8B; hemophilia A; Antihemophilic factor; Procoagulant component; coagulation factor VIII; coagulation factor VIIIc; coagulation factor VIII; OTTHUMP00000061446; OTTHUMP00000196174; Coagulation factor VIII; Factor VIIIa heavy chain, 200 kDa isoform; Factor VIIIa heavy chain, 92 kDa isoform; Factor VIII B chain; Factor VIIIa light chain
• Gene ID: 2157
• mRNA Refseq: NM_000132
• Protein Refseq: NP_000123
• MIM: 300841
• UniProt ID: P00451
• Chromosome Location: Xq28
• Pathway: Complement and coagulation cascades; Hemostasis
• Function: copper ion binding; oxidoreductase activity; protein binding

Reviews

01/04/2023

The F8 protein is of exceptional quality and has proven to be an ideal choice to meet my experimental requirements.

04/26/2019

Its purity and reliability have consistently resulted in successful outcomes in my research projects, providing me with accurate and reproducible data.

06/17/2017

With its consistent and outstanding results, the F8 protein is an indispensable tool that I highly recommend for researchers in need of reliable and precise protein analysis.

Q&As

How has technology advanced the production of F8 protein for therapeutic purposes?

Recombinant DNA technology allows for the production of F8 protein in laboratory settings, reducing the risk of contamination and increasing availability.

Can F8 protein therapy be administered at home by patients?

Many patients can self-administer F8 protein therapy at home after proper training, providing convenience and improving overall quality of life.

Are there alternative treatment approaches for hemophilia A involving F8 protein?

Gene therapy is being explored as a potential alternative, aiming to introduce functional F8 genes into patients' cells to produce the missing protein.

How does monitoring F8 protein levels contribute to hemophilia A management?

Regular monitoring helps determine the appropriate dosage for replacement therapy, ensuring that F8 levels remain within the therapeutic range.

Are there any complications associated with F8 protein replacement therapy?

In some cases, individuals may develop inhibitors—antibodies that neutralize the therapeutic F8 protein—leading to challenges in treatment.